Navigation Links
Bioniche Warrants' Expiration Date to be Extended
Date:2/17/2009

- will be delisted then extended as unlisted warrants to May 12, 2009 -

BELLEVILLE, ON, Feb. 17 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, announced today that it will extend the expiration date of the up to 8,203,334 common share purchase warrants issued as part of a unit offering that closed in March, 2007. 7,676,554 of these warrants, currently listed for trading on the TSX (TSX: BNC.WT), will be delisted following their original expiration date of March 13, 2009. At that time, the Company will extend the expiration date of the warrants to May 12, 2009, subject only to the filing of final documentation with the Toronto Stock Exchange (TSX).

Each common share purchase warrant entitles the holder to purchase a common share at an exercise price of $1.40 per share.

The expiry date on a further 1,027,308 broker warrants will also be extended by 60 days to May 12, 2009. These are exercisable for units, each consisting of one Bioniche common share and one-half of a warrant to purchase a Bioniche common share at $1.20 per unit.

"Our Board of Directors took this decision to allow additional time for the investors in Bioniche to evaluate the Company's ongoing progress in achieving its stated objectives, in particular, addressing its near-term capital needs," said Graeme McRae, Chairman, President & CEO of Bioniche Life Sciences Inc. "The Board is of the opinion that recent market conditions have depressed the value of both the common shares and the common share purchase warrants. Advance notice of this extension fairly treats current and prospective warrant investors and is in conformance with TSX regulations."

The extension will not apply to warrants held by insiders of the Company.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bioniche Life Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Reports Fiscal 2009 Second Quarter
2. Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable
3. Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada
4. Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile
5. Bioniche Reports Fiscal 2009 First Quarter
6. Bioniche Allows Conversion of Portion of Revolving Credit Facility
7. Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary
8. Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference
9. Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production
10. Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia
11. Bioniche Presents Pre-Clinical Research at Two International Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... Springs, FL (PRWEB) , ... February 13, 2016 , ... ... the environmental impact of American businesses. , The increasingly modern world of instantaneous ... more often on non-renewable energy sources such as oil and coal, which pollutes our ...
(Date:2/13/2016)... ... 2016 , ... DDi , a Makro company, makes ... its expertise in eClinical Solutions. DDi has built its solution competency with a ... global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
(Date:2/12/2016)... ... 12, 2016 , ... Coco Libre, the maker of coconut water beverages with ... Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic ... The invitation-only gifting suite, held this year at the W Hollywood Hotel, has become ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and ... J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA ... Southern Nevada Healthcare System. This will be the first Fisher House in Nevada, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Affairs leaders at pharmaceutical organizations are looking to either start or ... some companies have conducted a significant number of clinical trials in ... as India and China ... India are now requiring local clinical trials to win ... China and India are ...
(Date:2/12/2016)... , Feb. 12, 2016  Innophos Holdings, Inc. (NASDAQ: ... specialty ingredients, today announced that it will host a live ... ET to discuss its fourth quarter and full year 2015 ... The press release detailing fourth quarter and full year results ... close. --> --> ...
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
Breaking Medicine Technology: